The Petco Foundation and the Blue Buffalo Foundation have partnered to sponsor a $1 million grant for Morris Animal Foundation to help fund research on osteosarcoma in dogs, according to a Feb. 24 announcement from MAF.
“Morris Animal Foundation continues to invest in groundbreaking osteosarcoma research, and we are deeply appreciative of the Petco Foundation and the Blue Buffalo Foundation for their support of this important work,” said Dr. John Reddington, president and chief executive officer of the Morris Animal Foundation, in the announcement. “This grant will help in our efforts to develop interventions to improve quality of life and survival time for our canine companions with this devastating disease.”
According to the announcement, current osteosarcoma statistics are grim:
- Osteosarcoma is diagnosed in 10,000 dogs in the United States each year.
- 4,000-8,000 dogs die every year from metastatic disease.
- In 90 percent of dogs, osteosarcoma already has spread at the time of diagnosis.
- 80 percent of dogs die within two years of diagnosis.
Safe and effective treatment options are available to treat the primary cancer, but better treatments are needed to stop metastasis. The new grant will help fund innovative approaches to combat metastatic osteosarcoma.
Other osteosarcoma studies at Morris Animal Foundation have focused on ways to optimize chemotherapy selection, control pain, and find new therapeutic targets.
Related JAVMA content:
Analyses delve into osteosarcoma prevalence, veterinary pricing (April 15, 2017)